226 related articles for article (PubMed ID: 32998939)
21. Current Status of Chemoprevention in Barrett's Esophagus.
Moayyedi P; El-Serag HB
Gastrointest Endosc Clin N Am; 2021 Jan; 31(1):117-130. PubMed ID: 33213791
[TBL] [Abstract][Full Text] [Related]
22. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.
Beales IL; Vardi I; Dearman L
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):917-23. PubMed ID: 22569083
[TBL] [Abstract][Full Text] [Related]
23. Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis.
Thrift AP
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2225-32. PubMed ID: 25835331
[TBL] [Abstract][Full Text] [Related]
24. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Choi SE; Perzan KE; Tramontano AC; Kong CY; Hur C
Cancer Prev Res (Phila); 2014 Mar; 7(3):341-50. PubMed ID: 24380852
[TBL] [Abstract][Full Text] [Related]
25. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort.
Krishnamoorthi R; Borah B; Heien H; Das A; Chak A; Iyer PG
Gastrointest Endosc; 2016 Jul; 84(1):40-46.e7. PubMed ID: 26772891
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus.
de Jonge PJ; Steyerberg EW; Kuipers EJ; Honkoop P; Wolters LM; Kerkhof M; van Dekken H; Siersema PD
Am J Gastroenterol; 2006 Jul; 101(7):1421-9. PubMed ID: 16863542
[TBL] [Abstract][Full Text] [Related]
27. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
28. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Wang F; Lv ZS; Fu YK
Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
[TBL] [Abstract][Full Text] [Related]
29. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis.
Alexandre L; Clark AB; Bhutta HY; Holt S; Lewis MP; Hart AR
Gastroenterology; 2014 Mar; 146(3):661-8. PubMed ID: 24315828
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma.
Thomas T; Loke Y; Beales ILP
J Gastrointest Cancer; 2018 Dec; 49(4):442-454. PubMed ID: 28691139
[TBL] [Abstract][Full Text] [Related]
31. Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study.
Arai J; Niikura R; Hayakawa Y; Kawahara T; Honda T; Hasatani K; Yoshida N; Nishida T; Sumiyoshi T; Kiyotoki S; Ikeya T; Arai M; Suzuki N; Tsuji Y; Yamada A; Kawai T; Koike K
Digestion; 2022; 103(3):192-204. PubMed ID: 34929693
[TBL] [Abstract][Full Text] [Related]
32. Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.
Beales IL; Dearman L; Vardi I; Loke Y
Dig Dis Sci; 2016 Jan; 61(1):238-46. PubMed ID: 26386857
[TBL] [Abstract][Full Text] [Related]
33. Chemoprevention in Barrett's Esophagus: Current Status.
Zeb MH; Baruah A; Kossak SK; Buttar NS
Gastroenterol Clin North Am; 2015 Jun; 44(2):391-413. PubMed ID: 26021201
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.
Runge TM; Abrams JA; Shaheen NJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):203-31. PubMed ID: 26021191
[TBL] [Abstract][Full Text] [Related]
35. Metabolic syndrome and risk of esophageal adenocarcinoma in elderly patients in the United States: An analysis of SEER-Medicare data.
Drahos J; Ricker W; Pfeiffer RM; Cook MB
Cancer; 2017 Feb; 123(4):657-665. PubMed ID: 27861759
[TBL] [Abstract][Full Text] [Related]
36. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus.
Kantor ED; Onstad L; Blount PL; Reid BJ; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):456-61. PubMed ID: 22241250
[TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.
Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM
Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286
[TBL] [Abstract][Full Text] [Related]
38. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
39. Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma.
Wennerström EC; Risques RA; Prunkard D; Giffen C; Corley DA; Murray LJ; Whiteman DC; Wu AH; Bernstein L; Ye W; Chow WH; Vaughan TL; Liao LM
Cancer Med; 2016 Sep; 5(9):2657-65. PubMed ID: 27384379
[TBL] [Abstract][Full Text] [Related]
40. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options.
Neumann H; Mönkemüller K; Vieth M; Malfertheiner P
Dig Dis; 2009; 27(1):18-23. PubMed ID: 19439956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
